EUVIMEDEUVIMED entdecken
Crossref

Safety risks of intratracheal lipid nanoparticle gene delivery to the lung and potential mitigation strategies

Akihiro Nagoya, Kumi Nakajima, Jenny Yune, Aizhou Wang, Zehong Guan, Yue Xu, Songtao Dong, Amy Strilchuk, Bowen Li, Stephen Juvet, Marcelo Cypel, Mingyao Liu und 1 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2026-05 · 171 (5) · 1159-1168.e6

DOI: 10.1016/j.jtcvs.2025.10.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-05. Verfasst von Akihiro Nagoya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Un…. Hauptthemen laut MEDLINE: Nanoparticles, Lung, Gene Transfer Techniques, Lipids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: University Health Network, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficiency and protein expression profiles of newly synthesized lipid nanoparticles (LNPs) as a nonviral vector gene delivery platform for gene editing of donor lungs for immunomodulation. METHODS: mCherry mRNA was formulated with 10 LNP candidates (5 ionizable lipids × 2 helper lipids), and gene delivery efficiency in cell lines was assessed using flow cytometry. The most promising LNP was optimized, and its protein expression was compared with that of adenoviral vectors (ADVs) using an mCherry enzyme-linked immunosorbent assay ELISA in a human precision-cut lung slice (PCLS) model. Additionally, intratracheal administration in a rat in vivo model was used to evaluate the relationship between LNP dose and protein expression using mCherry and human interleukin-10 (hIL-10) mRNA. RESULTS: An ionizable lipid ST-1 (formulated with 1,2-dioleoyl-3-trimethylammonium-propane [DOTAP]) achieved high transfection rates of 91.3 ± 6.9% in human lung epithelial cells and 88.4 ± 6.3% in human monocytic cells. Reducing the DOTAP content from 39% to 7.8% further improved the transfection rate. Peak mCherry expression in human PCLS with ST-1 DOTAP (7.8%) occurred at 2 days postadministration, which was faster than with adenoviral vectors. Intratracheal administration of 500 μg/kg of ST-1 DOTAP (7.8%) with mCherry to rat left lungs caused significant lung injury; however, 50 μg/kg of hIL-10 mRNA mitigated the LNP-induced lung inflammation, achieving the target concentration of 59 pg/mg protein in the left lung. CONCLUSIONS: LNPs achieved rapid and efficient protein expression in vitro and in vivo that exceeded the performance of viral vectors; however, significant lung injury was observed with intratracheal LNP administration. This findings underscores the need to further optimize LNP-mediated gene delivery to the lung before translation to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLungGene Transfer TechniquesLipidsGenetic TherapyAnimalsHumansInterleukin-10TransfectionRatsRats, Sprague-DawleyMaleGenetic VectorsAdenoviridaeRNA, MessengerLiposomes

Stichwörter der Autor:innen

gene deliveryinflammationinterleukin-10lipid nanoparticlelung transplantation

Substanzen

LipidsInterleukin-10Lipid NanoparticlesIL10 protein, humanRNA, MessengerLiposomes

Autor:innen und Institutionen

  • Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
  • Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address: sha…

Förderung

  • University Health Network
  • Canadian Institutes of Health Research

Zitieren

APA

Nagoya, A., Nakajima, K., Yune, J., Wang, A., Guan, Z., Xu, Y., Dong, S., Strilchuk, A., Li, B., Juvet, S., Cypel, M., Liu, M., & Keshavjee, S. (2026). Safety risks of intratracheal lipid nanoparticle gene delivery to the lung and potential mitigation strategies. The Journal of Thoracic and Cardiovascular Surgery, 171(5), 1159-1168.e6. https://doi.org/10.1016/j.jtcvs.2025.10.021

Vancouver

Nagoya A, Nakajima K, Yune J, Wang A, Guan Z, Xu Y, et al. Safety risks of intratracheal lipid nanoparticle gene delivery to the lung and potential mitigation strategies. The Journal of Thoracic and Cardiovascular Surgery. 2026;171(5):1159-1168.e6. doi:10.1016/j.jtcvs.2025.10.021

BibTeX
@article{Nagoya2026,
  author = {Nagoya, Akihiro and Nakajima, Kumi and Yune, Jenny and Wang, Aizhou and Guan, Zehong and Xu, Yue and Dong, Songtao and Strilchuk, Amy and Li, Bowen and Juvet, Stephen and Cypel, Marcelo and Liu, Mingyao and Keshavjee, Shaf},
  title = {Safety risks of intratracheal lipid nanoparticle gene delivery to the lung and potential mitigation strategies},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  volume = {171},
  number = {5},
  pages = {1159--1168.e6},
  doi = {10.1016/j.jtcvs.2025.10.021}
}
Kostenlos starten →